Newcastle biotech InvenireX has appointed veteran tech leader Alastair Carrington as non-executive chair following a recent £500,000 investment by DSW Ventures and XTX Ventures.
Carrington brings a wealth of experience in commercial strategy and leadership, particularly in the deep tech sector, to help position InvenireX at the forefront of the diagnostics market. During his career he has held senior roles with companies including Cambridge-based Expedeon and Stirling-based Integrated Graphene, and is currently CEO of Newcastle-based Atelerix.
The appointment follows the sizeable recent investment and comes as the company prepares to launch its first commercial pilot studies.
Doug Quinn, partner at DSW Ventures, said: “Alastair’s appointment is another key step for InvenireX. His experience in bringing R&D innovations to market is exactly what the company needs to help guide it through the commercialisation process, identify lucrative opportunities and ensure a smooth roll-out.”
Daniel Todd, co-founder and CEO of InvenireX, added: “Having Alastair on board is a game changer for us. His expertise will be invaluable in helping us navigate the complex terrain of launching a disruptive new technology. With his guidance, we can avoid common pitfalls and successfully introduce our novel diagnostic solutions to the market.”
Carrington said: “I am truly impressed by the dedication and speed of innovation at InvenireX. The team’s ambition to disrupt and enhance scientific understanding through single nucleotide detection is not just exhilarating; it’s also profoundly important. It’s an exciting challenge to help steer such a dynamic company from a start-up to become a major disruptor in the industry.”
InvenireX aims to revolutionise the field of molecular diagnostics molecular analysis with its advanced AI and ‘nanite’ technology. Its AI-driven platform has potential for ultra-early disease detection, personalised medicine and environmental monitoring.
